Results of a world-first phase 3 trial for secondary progressive multiple sclerosis (MS), led by UCL researchers, have shown ...
Confirmed six-month disability progression rates over 4 years were similar in patients given the oral statin or a placebo in ...
PRESS RELEASE AB SCIENCE PROVIDES AN UPDATE ON THE DEVELOPMENT OF MASITINIB IN PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS POST ECTRIMS 2024 Paris, 23 September 2024, 5.45pm CET AB Science SA (Euronext - ...
MedPage Today on MSN19h
McDonald Criteria Revisions Signal Shift Toward MS as a Biologically Based DiseaseThe revisions signal a shift toward looking at MS more as a biologically based disease, noted Xavier Montalban, MD, PhD, of ...
Candidates participating in this year’s general election were invited to submit information to the League of Women Voters of ...
Osteopenia was originally a qualitative term denoting bone that appeared to be less dense on radiographs. Since 1994, it has ...
Visit us on Facebook. Opens in a new tab or window Visit us on X. Opens in a new tab or window Visit us on Instagram. Opens in a new tab or window Visit us on LinkedIn. Opens in a new tab or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback